Amarin Corp Plc (AMRN) trades on Nasdaq and is classified in the Technology sector. Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States. This page tracks AMRN using verified market data, the company's most recently reported financial statements, its earnings record and Ticker-Terminal's analytical models. Every figure is shown with its source and the time it was last verified, and values we cannot verify are labelled rather than filled in.
Previous close
$11.60
Volume
51,008
52-week range
$11.34 – $20.90
Market cap
$244.6M
Source: Polygon (snapshot) · Verified Oct 14, 2026, 3:59 PM EDT
1D
+0.26%
1W
-3.41%
1M
-17.07%
1Y
-39.91%
Percentage change calculated from verified closing prices. Periods without full provider coverage are marked unavailable rather than estimated.
Revenue (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue growth (YoY)
Reported Q2'26 · Polygon (company financials)
EPS (TTM, diluted)
Reported Q2'26 · Polygon (company financials)
EPS growth (YoY)
Reported Q2'26 · Polygon (company financials)
Gross margin
Reported Q2'26 · Polygon (company financials)
Operating margin
Reported Q2'26 · Polygon (company financials)
Net margin
Reported Q2'26 · Polygon (company financials)
Operating cash flow (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue 2-year CAGR
Reported Q2'26 · Polygon (company financials)
Source: Polygon financials + Finnhub earnings · Latest reported Q2'26 · Verified Jul 28, 2026, 8:00 PM EDT
P/E (trailing)
Trailing earnings are negative, so a trailing P/E is not meaningful.
P/E (forward, est.)
Market cap
Polygon / Finnhub reference
Dividend yield
Ticker-Terminal does not publish a dividend yield for this ticker until a verified distribution is on file.
Next earnings date
Oct 26, 2026
Source: Finnhub earnings calendar
Latest reported quarter
Q2'26
Revenue $42.2M · Diluted EPS -0.02
| Period | EPS actual | Estimate | Surprise |
|---|---|---|---|
| 2026-06-30 | 0.04 | -0.01 | +492.2% |
| 2026-03-31 | -0.09 | 0.09 | -203.8% |
| 2025-12-31 | 0.01 | 0.00 | — |
| 2025-09-30 | 0.08 | -0.58 | +113.8% |
Analysis temporarily unavailable because required market data could not be verified.
Analysis temporarily unavailable because required market data could not be verified.
Rating
Underperform
Average target
Unavailable
Range
Unavailable
Analysts
7
Source: finnhub
Some data is delayed, stale or unavailable. Everything shown is still verified.
Company profile and business overview · Reported financial statements · Earnings history
This page is the free public summary. Inside Ticker-Terminal you get quarterly forecasts, EPS estimate tracking, earnings deep dives, fair-value modelling and AI research built on the same verified provider data and filings.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
Amarin Corp Plc trades under the ticker AMRN on Nasdaq.
AMRN was last verified at $11.63 (0.26% on the day). After hours, last verified Oct 14, 2026, 3:59 PM EDT. Market data may be delayed and is shown with its own timestamp.
Based on the latest reported financials, AMRN revenue changed -42.0% year over year (filed Jul 28, 2026).
The next confirmed AMRN earnings date is Oct 26, 2026, per Finnhub earnings calendar. Dates can be revised by the company.
For Q2'26, AMRN reported revenue of $42.2M and diluted EPS of -0.02.
Create a free Ticker-Terminal account to run a full AI research report on AMRN — earnings breakdown, quarterly forecasts, bull, base and bear cases, and fair value ranges built on verified provider data and filings.
Free guide series
Two emails. The 7-step checklist now, then the next guide in the series — starting with Which AI is best for stock research.
Market data on this page is supplied by third-party providers, may be delayed, and is shown with the time it was last verified. Financial figures come from AMRN's most recently reported statements and are not restated by Ticker-Terminal.
Scores, fair-value ranges and bull, base and bear scenarios are analytical models calculated from verified data. They are educational information, not investment advice, not a price prediction, and not a recommendation to buy or sell any security. Past performance does not indicate future results.
See our risk disclosure. Page data assembled Oct 14, 2026, 6:26 PM EDT.